The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
European Association for the Study of Diabetes September 27 – October 1, 2021
Presentations of the Scientific Symposium at the EASD 57th Annual Meeting 2021
Thank you for your interest! Please see below to download PDFs of the presentation of the Scientific Symposia at the EASD Congress 2021. Access to the presentations will be available after the congress presentation.
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Finerenone
Friday 1 October, 2021 | 11:15 - 11:25 CEST
Finerenone – a new approach to kidney protection in patients with T2D
New directions in kidney care in diabetes: Targeting mineralocorticoid receptor overactivation with finerenone
Session: Scientific SymposiumSpeaker: Ralph DeFronzo
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Friday 1 October, 2021 | 11:25 - 11:40 CEST
Finerenone – a new approach to kidney protection in patients with T2D
FIDELIO-DKD: Cardiorenal outcomes in people with high risk CKD and T2D
Session: Scientific SymposiumSpeaker: George Bakris
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Friday 1 October, 2021 | 11:40 - 11:55 CEST
Finerenone – a new approach to kidney protection in patients with T2D
FIGARO-DKD: Cardiorenal outcomes across the broad spectrum of CKD and T2D
Session: Scientific SymposiumSpeaker: Luis Ruilope
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Friday 1 October, 2021 | 11:55 - 12:05 CEST
Finerenone – a new approach to kidney protection in patients with T2D
Navigating the data for key subgroup
Session: Scientific SymposiumSpeaker: Janet McGill
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Friday 1 October, 2021 | 12:05 - 12:15 CEST
Finerenone – a new approach to kidney protection in patients with T2D
Maintaining the course: Safety considerations for optimising patient outcomes
Session: Scientific SymposiumSpeaker: Andreas Birkenfeld
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Friday 1 October, 2021 | 12:15 - 12:25 CEST
Finerenone – a new approach to kidney protection in patients with T2D
Setting the route for CKD and T2D care: Clinical consequences of the FIDELIO-DKD and FIGARO-DKD data
Session: Scientific SymposiumSpeaker: Rajiv Agarwal
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
MA-M_FIN-ALL-0525-1